Rare disease focus Target opportunities in orphan/rare disease programs leveraging Catalyst’s core expertise in in-licensing, development, and commercialization of therapies, with a emphasis on patient access programs and payer support to accelerate market uptake.

Global expansion readiness Capitalize on Catalyst’s established US presence and ongoing push for global partnerships to propose international co-development and distribution deals, especially in markets with unmet needs in rare diseases.

Clinical real-world data Leverage the company’s planned real-world evidence presentations in Duchenne muscular dystrophy to position companion studies, post-market surveillance, and data-driven value propositions for payers and clinicians.

Strategic partnerships Propose collaborations with larger pharmas for licensing, co-marketing, or commercialization support to scale access across regions, aligning with Catalyst’s partnering strategy and Forbes-listed growth profile.

Stakeholder engagement Engage advocacy, patient groups, and sponsored summits like the Catalyst Advocacy Scholars Summit to create advocacy-driven market access initiatives, patient support programs, and streamlined enrollment pathways.